Bristol-Myers Squibb (BMY) CEO Caforio Says M&A Focused in Four Areas, Will Present Opdivo CHECKMATE-026 in Oct.

September 13, 2016 12:03 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Bristol-Myers Squibb Company (NYSE: BMY) participated in the Morgan Stanley 2016 Global Health Care Conference today. In part, CEO Giovanni Caforio said:

  • M&A targets are oncology, innumoscience, fibrosis, cardio
  • Opdivo CHECKMATE-026 data coming at ESMO in October

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Comments, Trader Talk

Related Entities

Morgan Stanley

Add Your Comment